Clinical Trial: A Phase 2 Dose Ranging Clinical Study to Evaluate the Efficacy and Safety of Frevecitinib (KN-002) in Patients With Severe Asthma

U.S., April 16 -- ClinicalTrials.gov registry received information related to the study (NCT07532265) titled 'A Phase 2 Dose Ranging Clinical Study to Evaluate the Efficacy and Safety of Frevecitinib (KN-002) in Patients With Severe Asthma' on April 08.

Brief Summary: A Phase 2 Dose Ranging Study to Evaluate the Efficacy and Safety of Frevecitinib (KN-002) Over a 12-Week Treatment Period in Patients With Severe Asthma Not Controlled With Medium to High Dose ICS/LABA

Study Start Date: June 01

Study Type: INTERVENTIONAL

Condition: Severe Asthma

Intervention: DRUG: Frevecitinib

Frevecitinib (KN-002) delivered via a dry powder inhaler (DPI)

DRUG: Placebo

Matching placebo to frevecitinib

Recruitment Status: NOT_YET_RECRUITING

Sponsor...